Table 1 Baseline characteristics
Parameter | N = 810 |
|---|---|
Age, years, mean (SD) | 45.9 (12.7) |
Disease duration, years, mean (SD) | 7.4 (10.1) |
Male gender, n (%) | 493 (60.9%) |
Current smoker, n/N (%)a | 139/542 (25.6%) |
Enrollment period, n (%) | |
    • 2006–2008 | 192 (23.7%) |
    • 2009–2012 | 173 (21.4%) |
    • 2013–2015 | 310 (38.3%) |
    • 2016–2017 | 135 (16.7%) |
Biologic naïve, n (%) | 703 (86.8%) |
nbDMARD use, n (%) | 169 (20.9%) |
    • Methotrexate | 120 (14.8%) |
    • Sulfasalazine | 49 (6.0%) |
    • Hydroxychloroquine | 13 (1.6%) |
    • Azathioprine | 7 (0.9%) |
    • Leflunomide | 7 (0.9%) |
NSAID use, n (%) | 532 (65.7%) |
Steroid use, n (%) | 95 (11.7%) |
Enthesitis, n/N (%)b | 156/721 (21.6%) |
Dactylitis, n/N (%)c | 39/484 (8.1%) |
CRP, mg/L, mean (SD) | 18.6 (62.3) |
ASDAS, mean (SD) | 3.7 (1.2) |
BASDAI, mean (SD) | 6.2 (2.1) |
BASFI, mean (SD) | 5.6 (2.4) |
Anti-TNF, n (%) | |
    • Golimumab | 421 (52.0%) |
    • Infliximab | 389 (48.0%) |